PRLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Prelude Therapeutics Inc (PRLD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown significant revenue growth, its financial performance remains weak with a substantial net income loss and declining EPS. The technical indicators show some bullish momentum, but the lack of significant positive catalysts, neutral insider and hedge fund activity, and absence of recent news or analyst upgrades make it less compelling as a long-term investment right now.
The stock's MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 69.537, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 3.222 and 3.488, with support at 2.358 and 2.092. However, the stock is trading flat in the regular market, with no significant price change.
Revenue increased significantly by 116.67% YoY in Q3 2025, and gross margin remains strong at 100%. Technical indicators show bullish momentum.
Net income dropped by -38.88% YoY, and EPS declined by -39.53% YoY. No recent news, analyst upgrades, or significant insider or hedge fund activity. Congress trading data is absent, and the stock shows a potential decline of -3.75% in the next month based on historical patterns.
In Q3 2025, revenue increased to $6.5M (up 116.67% YoY), but net income dropped to -$19.725M (down -38.88% YoY). EPS declined to -0.26 (down -39.53% YoY), reflecting weak profitability despite strong revenue growth. Gross margin remains at 100%.
No recent analyst rating or price target changes available.
